Nothing said here yet.
to join the conversation.
| David J. Taylor | Buy | $8.0K | Tue, Sep 22 | Thu, Oct 1 |
| David J. Taylor | Sell | $16.0K | Wed, Aug 26 | Thu, Sep 3 |
| Sheldon Whitehouse | Sell | $8.0K | Wed, Aug 12 | Wed, Sep 2 |
| Thomas H Tuberville | Sell | $32.5K | Tue, Apr 15 | Wed, Aug 5 |
| Alan Armstrong | Sell | $32.5K | Fri, Mar 27 | Tue, Jul 21 |
| David J. Taylor | Buy | $8.0K | Fri, Jun 5 | Thu, Jun 11 |
| Maria Elvira Salazar | Sell | $32.5K | Fri, Apr 17 | Fri, May 1 |
| Maria Elvira Salazar | Buy | $32.5K | Tue, Mar 24 | Wed, Apr 1 |
Amgen (AMGN) has been in focus after positive Phase 3 data for IMDELLTRA in extensive stage small cell lung cancer and Tezspire in eosinophilic esophagitis, alongside analysts lifting near term earnings expectations.
The latest trading day saw Amgen (AMGN) settling at $460.73, representing a +1.97% change from its previous close.
Beyond analysts' top-and-bottom-line estimates for Amgen (AMGN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2026.
Amgen heads into Q3 earnings with a CFO transition, a management warning about surging costs, and MariTide trials burning through cash.
Amgen (NasdaqGS:AMGN) reported new Phase 3 data for dazodalibep in Sjögren's disease at ACR Convergence 2026. The company shared long term safety and efficacy data for UPLIZNA in IgG4-related disease and additional rare autoimmune conditions.
Amgen heads into Q3 earnings with a four-quarter beat streak, but biosimilar competition, pricing pressure and higher costs may challenge growth.
Amgen's quarterly revenue swings between $8.1B and $10.1B, while Vertex climbs steadily from $2.8B to $3.3B—a tale of scale versus trajectory.